Hailan Lin

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 262 citations · Full text

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 243 citations

Hepatology, Medicine, Pathology +6

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Masatoshi Kudo, Zhenggang Ren, Yabing Guo et al. · The Lancet · 2025 · 161 citations

Hepatology, Non-metastatic Hepatocellular Carcinoma, Transarterial Chemoembolisation +8

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu et al. · EClinicalMedicine · 2024 · 119 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +9

Polycyclic Aromatic Hydrocarbon Detection by Electrochemiluminescence Generating Ag/TiO₂ Nanotubes

Juanxiu Li, Lixia Yang, Shenglian Luo et al. · Analytical Chemistry · 2010 · 98 citations